| |
Monday, April 21, 2025 | 12pm ET / 9am PT Join us for an exclusive webinar exploring groundbreaking findings from the DUTRENEO trial, which evaluated the role of predictive biomarkers in guiding neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Register today. 
|
|
Today’s Big NewsApr 10, 2025 |
|
Access this resource for key insights from industry leaders on the use of in-country liquid biopsy testing for global clinical trials. Country-specific regulations often prevent or delay access to testing results, decreasing population sizes and increasing timing and costs. Download now to see how to overcome these challenges. 
|
|
| By Gabrielle Masson More than 200 biotech leaders have penned a letter voicing concerns over the FDA’s capacity after mass layoffs, specifically for small biotechs that depend on investor backing to meet agency standards. |
|
|
|
By Kevin Dunleavy With fears increased in the healthcare industry that top executives could be targets of violence, some pharma companies have been beefing up security protocols for their CEOs. As U.S. drugmakers have released their proxy statements over the last few weeks, several reported large expenditures to protect their top execs. |
By Nick Paul Taylor Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech revealed plans to lay off 65% of its staff and operate with a skeleton crew to save money. |
By Kevin Dunleavy Merck has handed out another hefty raise to CEO Rob Davis, boosting his compensation by 13% to $23.2 million in 2024, according to the company’s 2025 proxy statement. |
|
Scaling advanced biotherapeutics is becoming more complex due to the rise of therapies like cell and gene treatments, RNA therapeutics and monoclonal antibody variants. Access this report to discover key strategies to optimize production, ensure compliance and accelerate commercialization. Download now. 
|
|
By Conor Hale The new system, for people with Type 1 or Type 2 diabetes ages 18 and up, boosts wear time by 50% over the current G7 sensor. |
By Fraiser Kansteiner After Sun Pharma appealed an injunction handed down in New Jersey federal court in November that blocked the U.S. launch of its alopecia med Leqselvi, the U.S. Court of Appeals for the Federal Circuit on Wednesday ruled in favor of the Indian drugmaker. Sun is no longer under any court order delaying or restricting Leqselvi’s market debut. |
By Nick Paul Taylor Ask a healthcare professional to name a psychiatric medicine and chances are they’ll say a brand approved at least 10 years ago. That finding, which comes from a ZoomRx survey, points to the challenge facing new market entrants as they try to wrestle mindshare from incumbents through marketing. |
By Nick Paul Taylor Alzheon’s attempt to rescue a once-failed idea for treating Alzheimer’s disease has flopped. Sixteen years after tramiprosate flunked a phase 3 trial, Alzheon’s prodrug form of the molecule has joined the lengthy list of pivotal Alzheimer’s failures. |
By Andrea Park After the success of a public service advertisement campaign aimed at improving recognition of the early signs of Alzheimer’s disease in Hispanic and Latino communities, the Alzheimer’s Association is expanding the PSAs’ reach to another group disproportionately affected by the disease. |
By Zoey Becker The company settled with several purchaser plaintiffs in an antitrust case that involved Jazz and generic Xyrem maker Hikma Pharmaceuticals. |
By Conor Hale The company’s SP SureForm 45 was greenlighted for use with its da Vinci SP system, spanning minimally invasive thoracic, colorectal and urologic procedures. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Senior Writer Paige Minemyer chats with Jason Oberfest, vice president of healthcare at Oura, to discuss how the company is approaching its push into healthcare. |
|
|---|
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Avoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
+(1)+(1).png)
